Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).

Abstract

5591Background: IO holds promise for EA with mismatch repair (MMR) or MSI-H phenotype, while trials of targeted agents matched by histology/single biomarkers have yet to meet clinical endpoints. We...